Italy

Italy remains a restrictive jurisdiction for classical psychedelics: access is generally limited to authorised clinical research, while many substances associated with psychedelic use are controlled under the national narcotics framework. The country's visible clinical activity is concentrated in depression-related work, especially ketamine and esketamine, rather than in routine patient access to classical psychedelics.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Italy.

1
The practical psychedelic-adjacent market in Italy is concentrated in hospital psychiatry and anaesthesia, not retail or private wellness access.
2
Esketamine appears to be the clearest regulated pathway, with AIFA listing it as a Class H medicine and ClinicalTrials.gov showing an Italy-based real-world study in treatment-resistant depression.
3
Ketamine research activity in Italy is visible in depression and ECT-augmentation contexts, but this should not be read as general legal access for psychedelic use.
4
The presence of only a small number of linked trials and stakeholders suggests a narrow research ecosystem, likely centred on a few psychiatric and academic centres.
5
Recent official Italian drug-policy reporting continues to frame controlled substances through the existing national tables, with no obvious signal of broad liberalisation for classic psychedelics.

Research Snapshot

Blossom currently tracks 3 psychedelic clinical trials connected to Italy, including 2 active studies.

Active trials: 2
Total trials: 3
Stakeholders: 6
Events: 0

Top Compounds

Esketamine(2)
Ketamine(2)

Active Trial Preview

View all trials →

Medical Access Snapshot

Italy maintains a largely prohibition-based approach to classical psychedelics: most classic hallucinogens (psilocybin, MDMA, mescaline, DMT, 5-MeO-DMT, 2C-X, ibogaine, ayahuasca) are controlled under the DPR 309/1990 framework and may only be accessed in authorised clinical research or via tightly regulated medical channels when a licensed medicinal product exists. The one broadly available, reimbursed pharmaceutical in the psychedelic-adjacent space is esketamine (Spravato), which is classified for hospital use with national reimbursement (AIFA Class...

View trials→View stakeholders→Open access guide→

Regulatory Status

Italy's access position is still best described as medical-only and tightly controlled. The Ministry of Health points to the D.P.R. 309/1990 framework for narcotic and psychotropic substances, while AIFA's published medicines lists and early-access/off-label guidance show that authorised medicines may be used within regulated hospital or off-label pathways. Esketamine is listed by AIFA among Class H medicines, indicating hospital use, whereas ketamine remains a controlled medicine used in clinical settings and, in some circumstances, off-label under Italian rules; however, patient access outside medical supervision for classical psychedelics appears prohibited or highly restricted.